Fondazione Italiana Linfomi - Ets

This study tests a drug called loncastuximab tesirine given after a short course of chemotherapy for people with mantle cell lymphoma that has returned or not responded to previous treatments, including BTK inhibitors. About 49 adults aged 18 to 84 will take part. The goal is to …

This study tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy (BEGEV) helps people with Hodgkin's lymphoma that has returned or not responded to first treatment. About 122 adults aged 18-60 will receive the combination before a stem cell transplant.…

This study tests a drug called tislelizumab in 28 adults with Hodgkin lymphoma who cannot receive standard chemotherapy due to age or health reasons. The goal is to see if the drug can shrink or control the cancer. Participants receive the drug intravenously every 3 weeks for up …

This study tests a combination of two drugs, mosunetuzumab and zanubrutinib, in people with follicular lymphoma that has come back or not responded to prior treatment. The goal is to see if this combination can shrink or eliminate tumors. About 56 adults will receive the treatmen…

This study is for people with early-stage follicular lymphoma, a slow-growing blood cancer. It compares standard radiation therapy alone to radiation plus a drug called obinutuzumab. The goal is to see if adding the drug helps keep the cancer from coming back longer. About 190 pa…

This study tests whether adding daratumumab to two standard drugs (bortezomib and dexamethasone) can shrink tumors in people with a rare, aggressive blood cancer called plasmablastic lymphoma that has returned or not responded to prior therapy. About 28 adults will receive the co…

This study tests a combination of two drugs (rituximab and CC-99282) as a first treatment for older, frail patients newly diagnosed with diffuse large B-cell lymphoma who cannot receive standard chemotherapy. About 47 participants will receive this chemo-free regimen to see if it…

This study tests whether a personalized healthy lifestyle plan can improve quality of life for people who have survived certain types of lymphoma (Hodgkin lymphoma, DLBCL, or PMBCL). Participants must be between 18 and 50 years old and in remission for 3 to 10 years. The study wi…

This study is observing 130 adults with B-cell non-Hodgkin lymphoma who are scheduled to receive CAR-T cell therapy. Researchers want to see if having low muscle mass (sarcopenia) affects how well the treatment works or causes more side effects. Participants will not receive any …

This study watches 1,500 people with B-cell non-Hodgkin lymphoma who are getting new antibody treatments in Italian clinics. Researchers will track how many patients respond, how long they stay well, and what side effects occur. The goal is to see how these drugs work outside of …

This study will review medical records from 200 people diagnosed with plasmablastic lymphoma, a rare and aggressive blood cancer. Researchers aim to learn more about the disease's features, treatments used, and what affects patient survival. No new treatments are given; the goal …

This study analyzes stored blood and tissue samples from 654 people with follicular lymphoma to investigate genetic changes (EZH2 and others) and how they relate to treatment outcomes. The goal is to learn more about the disease, not to test a new treatment. Participants are from…

This study is collecting information from 43 people diagnosed with primary cardiac lymphoma, a rare cancer of the heart, in Italy between 2000 and 2020. The goal is to learn more about the disease and how it is managed, which may help doctors in the future. No new treatments are …

This study collects information from medical records of 400 adults with cutaneous T-cell lymphoma to see which systemic (body-wide) treatments doctors actually use and in what order. It aims to describe real-world treatment patterns, not to test a new drug. Participants must have…

This study looks at how changes in the MYC gene relate to the immune environment and treatment outcomes in people with diffuse large B-cell lymphoma or high-grade B-cell lymphoma. Researchers will collect data from 200 patients to understand these links better. No new treatments …

This study follows 150 elderly patients (70 years or older) with low-grade non-Hodgkin lymphoma to see how their quality of life changes during treatment. Researchers will use questionnaires to measure well-being and symptoms at the start, end, and one year after therapy. The goa…